ASGCT News

Filter By

Recent Articles

How to Access Today's Free Professional Development Café

ASGCT Staff | January 21, 2022

Join us from 1-3 p.m. (CT) for "How To" with CAR T-Cell Therapy.

Read Full Story

Two Free Virtual Sessions: Long COVID and International Trainees

Grant Holley, PhD | January 12, 2022

Each two-hour session is FREE for ASGCT members and only $50 for non-members!

Read Full Story

Register Now for the 25th Annual Meeting

ASGCT Staff | December 15, 2021

We look forward to being back in person this spring in our largest venue yet!

Read Full Story

How to Access Today's Free Professional Development Café

ASGCT Staff | December 03, 2021

Join us from 1-3 p.m. (CT) for Critical CMC Issues for Gene and Cell Therapy Products.

Read Full Story

ASGCT Members Provide Recommendations During FDA Liaison Meeting

ASGCT Staff | November 23, 2021

Society members spoke on three significant topics in the field during the Nov. 8 liaison meeting.

Read Full Story

Gene Therapy Strategies for Diabetic Eye Diseases

Nachi Pendse, PhD | November 23, 2021

In this blog post, Patricia D’Amore, PhD, MBA; Sui Wang, PhD; and Nachi Pendse, PhD; shared some of their insights on how cell and gene therapy can help patient populations with diabetic eye disorders.

Read Full Story

Gene and Cell Therapies: A Breath of Fresh Air for Lung Cancer Treatment?

Eoghan J. Mulholland, PhD | November 18, 2021

To recognize Lung Cancer Awareness Month, Dr. Eoghan Mulholland describes how gene and cell therapies could eventually lead to the treatment and prevention of this disease.

Read Full Story

Submit Your Abstracts for the 25th Annual Meeting

ASGCT Staff | November 16, 2021

The call for abstracts is open through February 2, 2022.

Read Full Story

OTAT Announces Growth Program at ASGCT/FDA Liaison Meeting

ASGCT Staff | November 12, 2021

Learn about the new OTAT program and view presentation slides from ASGCT's fourth annual liaison meeting with the FDA this week.

Read Full Story

How to Access Today's Free Professional Development Café

ASGCT Staff | November 12, 2021

Join us from 1-3 p.m. (CT) for Staying Strong: You Are Not Alone.

Read Full Story

Learning About CRISPR from a Genome Editor

Kenji Rowel Lim | November 01, 2021

“We’re able to modify the genome now in ways that we simply could not imagine several years ago,” Ben Kleinstiver, PhD, told attendees during ASGCT's most recent Professional Development Café.

Read Full Story

Booster Shots Are Safe and Effective

Edith Pfister, PhD | October 29, 2021

The FDA recently authorized additional doses of the Pfizer, Moderna, and Johnson & Johnson vaccines for COVID-19.

Read Full Story

ASGCT Joins National Partnership to Accelerate Gene Therapy Development for Rare Diseases

ASGCT Staff | October 27, 2021

The new effort aims to make gene therapy more accessible by creating a development template that can be used repeatedly to expedite the delivery of novel therapies for many different genetic disorders.

Read Full Story

Read ASGCT's Third Quarter Landscape Analysis Field Report

ASGCT Staff | October 22, 2021

The third quarterly publication from ASGCT and Informa Pharma Intelligence, the Gene, Cell, & RNA Therapy Landscape report, is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

Read Full Story

ASGCT Symposium Catalyzes Discussions to Expand Reach of Gene Therapy in India

Savita Rangarajan, MD, and Jayandharan Rao, PhD | October 19, 2021

The goal of the Oct. 9 event was to explore how to facilitate gene therapy clinical research to ultimately expand patient access to therapies in India in the future.

Read Full Story

Paloma Giangrande, PhD, is Not Afraid to Push Herself Out of Her Comfort Zone

ASGCT Staff | October 18, 2021

The incoming editor-in-chief of Molecular Therapy Nucleic Acids will assume her role on January 1, 2022, replacing John Rossi, PhD.

Read Full Story
2022

ASGCT 25th Annual Meeting

May 16-19, 2022

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.